2019
DOI: 10.1016/j.coph.2019.01.003
|View full text |Cite
|
Sign up to set email alerts
|

Recent advances of anti-cancer therapies including the use of cell-penetrating peptides

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
17
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 38 publications
(17 citation statements)
references
References 52 publications
0
17
0
Order By: Relevance
“…These excellent results encouraged us to test the potential of the helical responsive MP1 for the transport of antibodies, [5][6][7]40,60,61 which was evaluated with mouse monoclonal Mab414 against the nuclear pore complex proteins ( Fig. 6 and Fig.…”
Section: Transport Of Antibodiesmentioning
confidence: 99%
See 1 more Smart Citation
“…These excellent results encouraged us to test the potential of the helical responsive MP1 for the transport of antibodies, [5][6][7]40,60,61 which was evaluated with mouse monoclonal Mab414 against the nuclear pore complex proteins ( Fig. 6 and Fig.…”
Section: Transport Of Antibodiesmentioning
confidence: 99%
“…5,39 Nevertheless, most of the recently developed synthetic transporters incorporate a high number of cationic residues and/or show strong amphiphilic character, which can easily destroy membranes and cause toxicity. 6,40 Despite a high number of charges could interfere with anionic biomolecules and cause toxicity, certain reported peptides reduce these limitations by controlling their membranolytic activity, such as RALA, 41 which requires endosomal pH acidification. Despite these clear precedents, little attention has been focused on the development of rational strategies for the design of membrane targeted molecules with selective and transient non-lytic membrane disruption and with a minimum number of cationic and hydrophobic residues.…”
Section: Introductionmentioning
confidence: 99%
“…While delivery into target cells or tissue types has not been extensively explored with regards to HIV-1, the use of nanoparticles [92,100,101], liposomes [101][102][103][104], cell-penetrating peptides [105,106], receptor-mediated targeting [107][108][109] and aptamers [110][111][112] have been assessed for use in cell based-therapeutic approaches. Further, results from our lab suggest that lncRNAs can be successfully targeted using either siRNA conjugates [113] or antisense oligonucleotides encapsulated in either nanoparticles or exosomes [114] to potentially mediate positive therapeutic outcomes.…”
Section: Lncrnas As Therapeutic Targets For Hiv-1mentioning
confidence: 99%
“…The protein also offers the possibility to insert peptides at the N and C-terminus, as well as in a loop containing amino acid residues 59–66, for display on the surface of intact virions or CP assemblies [38]. This latter property is interesting because peptides and in particular cell-penetrating peptides have clear beneficial effects in the context of cancer disease [39,40,41]. Among the different therapeutic approaches in which peptides are used, a recent strategy involves a “membrane-targeting peptide” (MTP) of 30 amino acids that mimics the transmembrane segment of NRP1 (MTP-NRP1).…”
Section: Introductionmentioning
confidence: 99%